Apr 05, 2012, 10.58 PM | Source: CNBC-TV18
Bio-pharma major Biocon on expansion mode.
Biocon is banking on a strong research pipeline. The company's focus on oral insulin will continue.
Kiran Mazumdar-Shaw, chairman and managing director, Biocon
says, the big change in our strategy would be that from having one global partner which was Pfizer, we'll have multiple partners.
Speaking to CNBC-TV18 Kiran Mazumdar Shaw, CMD, Bi
"Suresh has over 30 years of experience in the pha
Biocon has informed that Suresh Subramaniam has be
Ashwani Gujral of ashwanigujral.com is of the view
The centre, named Syngene Amgen Research and Devel